Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antihypertensive Drugs: Action of Calcium Channel Blockers

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of platelet derived growth factor-BB levels in injectable platelet rich fibrin coated graft using gingival pedicle split thickness tunnel technique for isolated gingival recession: A randomized controlled trial.

The Saudi dental journal·2024

Same author

Augmentation of Peri-implant Keratinized Mucosa Using a Combination of Free Gingival Graft Strip with Xenogeneic Collagen Matrix or Free Gingival Graft Alone: A Randomized Controlled Study.

The International journal of oral & maxillofacial implants·2023

Same author

Second-Generation Liquid Platelet Concentrates: A Potential Boon for Regenerative Dentistry.

Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)·2022

Same author

Efficacy of antimicrobial photodynamic therapy on the tongue surface in the management of halitosis - A real-time polymerase chain reaction analysis.

Photodiagnosis and photodynamic therapy·2022

Same author

Depigmenting effect of banana stem and flower on melanocytes.

Journal of oral biology and craniofacial research·2022

Same author

Patient-centered comparative outcome analysis of platelet-rich fibrin-reinforced vestibular incision subperiosteal tunnel access technique and Zucchelli's technique.

Journal of Indian Society of Periodontology·2021

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

Published on: January 12, 2019

Amlodipine-induced gingival overgrowth.

M G Triveni¹, C Rudrakshi, D S Mehta

¹Departments of Periodontology and Implantology, Bapuji Dental College and Hospital, Davangere, Karnataka, India.

Journal of Indian Society of Periodontology

|April 10, 2010

Summary

Amlodipine, a calcium channel blocker, can rarely cause gingival overgrowth. This case report details successful treatment involving drug substitution, surgery, and supportive care for this rare side effect.

Keywords:

Amlodipine calcium channel blockers gingival overgrowth

Related Experiment Videos

Last Updated: Jun 14, 2026

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

Published on: January 12, 2019

Area of Science:

Pharmacology
Periodontology
Oral Medicine

Background:

Gingival overgrowth is an exaggerated gingival response linked to various local and systemic factors.
Certain medications, including anticonvulsants, immunosuppressants, and calcium channel blockers, are known to induce gingival enlargement in susceptible individuals.
Amlodipine, a widely used calcium channel blocker for hypertension and angina, is rarely associated with this adverse drug reaction.

Observation:

A rare case of gingival overgrowth was observed in a 50-year-old female patient.
The patient was taking amlodipine, a calcium channel blocker medication.
The overgrowth presented as an over-exuberant gingival response.

Findings:

Amlodipine, despite its general safety profile, can rarely induce gingival overgrowth.
The presented case highlights a specific instance of this rare adverse drug reaction.
Successful management was achieved through a multi-faceted treatment approach.

Implications:

Clinicians should consider amlodipine as a potential cause of gingival overgrowth in patients presenting with such symptoms.
Comprehensive patient management, including drug substitution and surgical intervention, can lead to excellent clinical outcomes.
This case underscores the importance of recognizing and managing rare drug-induced side effects for optimal patient care.